Trial Profile
PRINCIPAL: A Prospective Observational Study of Real World Treatment Patterns and Treatment Outcomes in Patients With Advanced or Metastatic Renal Cell Carcinoma Receiving Pazopanib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRINCIPAL
- Sponsors GlaxoSmithKline; GSK; Novartis; Novartis Pharmaceuticals
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 12 Jul 2017 Status changed from recruiting to completed.